CE Geyer

Abstract S1-03: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer

DJ Slamon, SM Swain, Marc Buyse et al. · Cancer Research · 2013 · 92 citations

Medicine, Oncology, Pharmacology +17

Abstract S1-05: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy (tx) with letrozole (L) in postmenopausal women with hormone-receptor (+) breast cancer (BC) who have completed previous adjuvant tx with an aromatase inhibitor (AI): Results from NRG Oncology/NSABP B-42

EP Mamounas, Hanna Bandos, BC Lembersky et al. · Cancer Research · 2017 · 55 citations

Medicine, Oncology, Pharmacology +17

Abstract GS1-02: NSABP B-47 (NRG oncology): Phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) → weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+ or 2+ with negative FISH (HER2-Low IBC)

L. Fehrenbacher, RS Cecchini, CE Geyer et al. · Cancer Research · 2018 · 50 citations

Medicine, Oncology, Pharmacology +13

Abstract S5-5: Trastuzumab plus adjuvant chemotherapy for HER2-positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

Edward H. Romond, VJ Suman, J-H Jeong et al. · Cancer Research · 2012 · 47 citations

Medicine, Oncology, Pharmacology +17

Abstract S3-06: A phase III trial evaluating pCR in patients with HR+, HER2-positive breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) +/- estrogen deprivation: NRG Oncology/NSABP B-52

MF Rimawi, RS Cecchini, Priya Rastogi et al. · Cancer Research · 2017 · 41 citations

Medicine, Oncology, Pharmacology +15